X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Lupin Ltd with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs ACTAVIS (US) - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 LUPIN LTD   ACTAVIS
EQUITY SHARE DATA
    LUPIN LTD
Mar-16
ACTAVIS
Dec-14
LUPIN LTD/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs2,12717,503-   
Low Rs1,29410,676-   
Sales per share (Unadj.) Rs304.13,151.8-  
Earnings per share (Unadj.) Rs50.4-393.3-  
Cash flow per share (Unadj.) Rs60.7289.2-  
Dividends per share (Unadj.) Rs7.500-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs243.86,836.1-  
Shares outstanding (eoy) m450.58265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.64.5 125.8%   
Avg P/E ratio x33.9-35.8 -94.8%  
P/CF ratio (eoy) x28.248.7 57.9%  
Price / Book Value ratio x7.02.1 340.4%  
Dividend payout %14.90-   
Avg Mkt Cap Rs m770,7403,746,408 20.6%   
No. of employees `00016.421.6 75.7%   
Total wages/salary Rs m21,0770-   
Avg. sales/employee Rs Th8,379.638,799.0 21.6%   
Avg. wages/employee Rs Th1,289.00-   
Avg. net profit/employee Rs Th1,388.7-4,841.7 -28.7%   
INCOME DATA
Net Sales Rs m137,016838,058 16.3%  
Other income Rs m1,877-2,092 -89.7%   
Total revenues Rs m138,893835,966 16.6%   
Gross profit Rs m37,535107,660 34.9%  
Depreciation Rs m4,635181,470 2.6%   
Interest Rs m44626,434 1.7%   
Profit before tax Rs m34,330-102,335 -33.5%   
Minority Interest Rs m-880-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-7,507 0.0%   
Tax Rs m11,536-5,261 -219.3%   
Profit after tax Rs m22,707-104,581 -21.7%  
Gross profit margin %27.412.8 213.2%  
Effective tax rate %33.65.1 653.6%   
Net profit margin %16.6-12.5 -132.8%  
BALANCE SHEET DATA
Current assets Rs m97,790441,549 22.1%   
Current liabilities Rs m53,872322,019 16.7%   
Net working cap to sales %32.114.3 224.7%  
Current ratio x1.81.4 132.4%  
Inventory Days Days8558 146.0%  
Debtors Days Days12166 182.9%  
Net fixed assets Rs m86,379102,335 84.4%   
Share capital Rs m9010-   
"Free" reserves Rs m105,7350-   
Net worth Rs m109,8441,817,717 6.0%   
Long term debt Rs m53,739952,519 5.6%   
Total assets Rs m224,3783,331,277 6.7%  
Interest coverage x77.9-2.9 -2,714.4%   
Debt to equity ratio x0.50.5 93.4%  
Sales to assets ratio x0.60.3 242.7%   
Return on assets %10.3-2.3 -439.9%  
Return on equity %20.7-5.8 -359.3%  
Return on capital %21.2-3.0 -704.3%  
Exports to sales %49.10-   
Imports to sales %7.40-   
Net fx Rs m53,5980-   
CASH FLOW
From Operations Rs m-3,690143,911 -2.6%  
From Investments Rs m-69,434-344,578 20.2%  
From Financial Activity Rs m58,126193,603 30.0%  
Net Cashflow Rs m-14,998-7,064 212.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 64.16 Rs / USD

Compare LUPIN LTD With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare LUPIN LTD With: TORRENT PHARMA  PANACEA BIOTECH  IPCA LABS  SHASUN PHARMA  WYETH LTD  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views On News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Aug 18, 2017 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD 8-QTR ANALYSIS

COMPARE LUPIN LTD WITH

MARKET STATS